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Background: The objective of our study was to assess the prevalence and incidence
of HEV in people living with HIV (PLWH) in a Spanish national cohort.
Methods: Retrospective longitudinal study including PLWH recruited in the cohort of
adult HIV-infected patients of the AIDS Research Network in follow-up at 28 Spanish
hospitals with available serum samples in 2014 and 2015. All samples were tested for
HEV IgG, IgM, and RNA. Samples with detectable HEV viral loads were genotyped.
Prevalence and incidence of HEV infection were calculated.
Results: The study sample comprised 845 PLWH. At baseline, 101 patients were
positive for HEV IgG antibodies (11.9%), none had HEV IgM antibodies, and 2 presented
detectable HEV RNA (0.23%). Forty-two seroconverted for IgG, supposing a cumulative
incidence of 5.7%. One subject was positive for IgM (0.13%), and 2 showed detectable
HEV RNA (0.27%). One case was infected by the emergent HEV genotype 3ra.
Conclusion: Our study identifies one case of HEV 3ra genotype infection, the main host
of which is rabbit, showing a potential zoonotic role of this emerging genotype in Spain.
Keywords: hepatitis E, HIV, survey, genotype 3ra, seroprevalence
INTRODUCTION
Hepatitis E virus (HEV) is an emerging infectious disease worldwide. In Europe, the majority of
cases are related to local infections, represented by HEV genotype 3 (Aspinall et al., 2017). Although
HEV infection by this autochthonous genotype usually presents as subclinical or self-limiting acute
hepatitis, there are several related complications that substantially worsen the prognosis of the
infection (Faber et al., 2018). HEV genotype 3 has tropism for the peripheral and central nervous
system, producing neurological injury, including serious manifestations such as Guillen-Barré
syndrome (Dalton et al., 2017). On the other hand, immunosuppressed patients infected by HEV
genotype 3 could develop chronic infection (Kamar et al., 2008). Cases of chronic HEV infection
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have been described in transplant recipients, leukemia patients
treated with rituximab, patients on therapy with anti-tumoral
necrosis factor drugs, and subjects infected by HIV with a low
CD4 + cell count (Rivero-Juárez et al., 2020). Finally, in the
context of underlying liver disease, HEV infection can trigger
liver failure and may require liver transplantation (Frias et al.,
2018). Consequently, there are subsets of patients in whom
HEV could have a serious outcome. Among the population in
which HEV infections may have a worse prognosis, persons
living with HIV (PLWH) represent a high-sensitivity population
because of the high rate of advanced liver fibrosis due to
common hepatotropic virus coinfection and the underlying
immunosuppression (Rivero-Juarez et al., 2019).
In Europe, the main HEV genotype is 3 (Abravanel et al.,
2017; Oeser et al., 2019; Suin et al., 2019). Nevertheless, in
recent years, an important number of new viral strains have
emerged that encompass a growing caseload in countries such as
Switzerland, France, Belgium and Spain (Abravanel et al., 2017;
Caballero-Gómez et al., 2019; Oeser et al., 2019; Suin et al., 2019).
The emergence of these new strains has an important clinical
implication because the introduction of new viral strains could
have a negative impact in terms of an increased number of
symptomatic and worst prognosis cases (Oeser et al., 2019). In
addition, recently, there has been awareness about the zoonotic
behavior of several HEV viral strains, the main host of which are
lagomorphs and rodents (Abravanel et al., 2017; Sridhar et al.,
2018; Suin et al., 2019). These strains have been described in
a high proportion of patients with chronic hepatitis, suggesting
that those patients with underlying immunosuppression could
be more suitable for infection by these emerging viruses (Sridhar
et al., 2018; Sahli et al., 2019).
For these reasons, our study assessed the prevalence and
incidence of HEV, as well as the prevalence of chronic HEV




The cohort of adult HIV-infected patients of the AIDS Research
Network (CoRIS) is an open, prospective, multicentre cohort
of adult subjects with confirmed HIV infection who are naïve
to antiretroviral therapy (ART) at cohort entry and who are
recruited to HIV care units of the Spanish Public Health System
(Caro-Murillo et al., 2007), which constitutes the standard place
of treatment for the great majority of persons in Spain. CoRIS was
launched in 2004. Each center recruits into the cohort all subjects
seen for the first time at the center who meet the following
criteria: confirmed HIV diagnosis, and naïve to ART. Written
informed consent is obtained from all patients. Demographic,
clinical, laboratory, microbiological and treatment information
is recorded. The cohort is linked to a centralized BioBank,
where patients’ blood samples are processed and cryopreserved
immediately after reception and then stored (García-Merino
et al., 2009). Participating centers are encouraged to obtain an
initial blood sample at entry in the cohort, preferentially before
starting ART, and follow-up samples preferentially annually,
or at least biannually thereafter. The BioBank has obtained
the UNE-EN-ISO 9001:2008 Systems of Quality Management
Requirements. For the proposed study, we included patients
recruited in the cohort at follow-up in 28 hospitals belonging
to 15 Spanish provinces with available serum samples in the
centralized BioBank in 2014 (baseline) and 2015.
HEV Serological and Molecular
Determination
First, all patients were tested for HEV IgG and IgM antibodies.
Serum samples were tested for anti-HEV IgG and IgM
(Wantai HEV-IgM ELISA R©; Beijing Wantai Biological Pharmacy
Enterprise© LTD, Beijing, China). ELISA tests were carried out
in duplicate in accordance with the instructions provided by
the manufacturer, using the automated ELISA Triturus System
(Grifols S. A, Barcelona, Spain). The cut-off value for positive
samples was > 1.1, following the manufacturer’s instructions.
Patients who were positive for HEV anti-IgG antibody at baseline
(prevalence) were not evaluated for IgG antibodies in the follow-
up (incidence).
Second, all patients were tested for HEV RNA using RT-
qPCR. RNA was extracted from 400 µL of serum pools of 4
patients using the commercial QIAamp MinElute Virus Spin
Kit (QIAgen. Hilden, Germany) and an automated procedure
(QIAcube. QIAgen, Hilden, Germany). The purified RNA was
eluted in a total elution volume of 30 µL. As a positive extraction
control, 50 µL of the reconstituted WHO Standard HEV strain
(supplied by the Paul-Ehrlich-Institute [code 6329/10]) was
diluted in 350 µL of Ambion R© DEPC-treated water (Thermo
Fisher Scientifics. Waltham, MA, United States). RT-qPCR was
performed on all pooled samples using the CFX Connect (Bio-
Rad, Hercules, California), using primer and probe designed and
validated by our group and described recently (Caballero-Gómez
et al., 2020). These primers and probes were obtained by aligning
all whole-genome sequences of the Orthohepeviridae A species
available in GenBank. The procedure was validated using the
WHO international reference panel for HEV RNA genotypes
for nucleic acid amplification technique (ıNAT)ı-based assays
(including genotypes 1a, 1e, 3b, 3c, 3e, 3f, 3ra, 4c, 4g, and
2a) supplied by the Paul-Ehrlich-Institut (code 8578/13). For
the reaction, the QIAgen One-Step PCR Kit (QIAgen, Hilden,
Germany) was used using 25 µL of RNA template. An external
(in-run) standard curve (using 18 dilutions) was used to calculate
the HEV viral load using the WHO Standard HEV strain (code
6329/10) with a unitage of 250,000 International Units/mL.
Positive pools were individually evaluated by the same RT-qPCR
procedure. The sensitivity of PCR in individual samples was 21
IU/mL, and in 4 samples-pools it was set at 350 IU/mL.
Samples with detectable HEV viral loads were genotyped
according to the protocol described by HEVnet. For phylogenetic
analysis, nested RT-PCR was performed, targeting the ORF2
region (structural proteins), using primers HEV_5920S (5′-
CAAGGHTGGCGYTCKGTTGAGAC-3′) and HEV_6425A
(5′-CAAGGHTGGCGYTCKGTTGAGAC-3′) in the first round
and HEV_5930S (5′-GYTCKGTTGAGACCWCBGGBGT-3′)
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and HEV_6334A (5′-TTMACWGTRGCTCGCCATTGGC-3′)
in the second round. The second amplification product of 467 bp
was sequenced using the BigDye Terminator Cycle Sequencing
Ready Reaction Kit on an ABI PRISM 3100 Genetic Analyzer
(Applied Biosystems, Foster City, CA, United States). SnapGene
software (Version 3.1; GSL Bio-tech, snapgene.com) was used for
sequence analysis. The consensus sequence was obtained using
SeqMan Software SeqMan NGen R© Version 12.0 (DNASTAR.
Madison, WI). Subtype assignment and phylogenetic analyses
were performed using the HEVnet genotyping tool1 (Mulder
et al., 2019), and confirmed by BLAST. Sequence alignments
were generated by the MAFFT online service: multiple sequence
alignment, interactive sequence choice and visualization.
Phylogenetic trees were constructed using the maximum
likelihood method using the proposed HEV genotype/subtype
standard reference (Smith et al., 2016). Reference sequences of
genotype 4 were included as an outgroup to root the tree. The
final tree was obtained with MEGA Software (Version 6) using
the bootstrap method (bootstrapped with 1000 replicates).
Statistical Analysis
Three outcome variables were established: (i) positivity for IgG
antibodies against HEV, (ii) positivity for IgM antibodies against
HEV, and (iii) detection of HEV RNA. These variables were
evaluated at baseline. The prevalence of IgG, IgM, and HEV
RNA was calculated. For those patients who were negative for
all outcome variables, three outcome variables were evaluated at
the end of the follow-up: (i) seroconversion for IgG antibodies
against HEV, (ii) seroconversion for IgM antibodies against HEV,
and (iii) detection of HEV RNA. The incidence rate of HEV
was calculated. The accumulated incidence was expressed as a
percentage. Continuous variables were expressed as the median
and quartiles (Q1–Q3). Student’s t-test, the Welch test or the
Mann-Whitney U-test was used to compare two independent
variables, and a Kruskal-Wallis test, one-way ANOVA or Welch
test was used to compare more than two independent variables.
The most appropriate test was chosen based on a normal
distribution (using the Shapiro-Wilk test) or equality of variances
(using the Levene test). Categorical variables were expressed as
the number of cases (percentage) compared using the χ2-test
or Fisher’s exact test. Significance was determined as a two-
tailed p-value of less than 0.05. Bivariate analysis comparing
the prevalence and incidence rate between groups was carried
out to identify variables related to the different outcome
variables. All analyses were carried out using the SPSS statistical
software package version 18.0 (IBM Corporation, Somers, NY,
United States), GraphPad Prism version 7 (Mac OS X version;
GraphPad Software; San Diego, California, United States) and
Winpepi software version 11.36 (Brixton Health).
Ethics
This study was designed and performed according to the Helsinki
Declaration. The local and national Clinical Trial and Ethical
Committee approved the study protocol.
1https://www.rivm.nl/mpf/typingtool/hev/
RESULTS
Study Population and Baseline
Characteristics
A total of 845 individuals were included in the study. Seven
hundred and fifty-one (88.9%) were male and had a median age of
36.9 years (30.7–45.2 years). Regarding HIV-related variables, 616
(72.9%) were men who had sex with men (MSM), and 80 (9.4%)
had prior AIDS-defining conditions, with a median CD4 + cell
count of 574 cells/mL (413–787 cells/mL), and 410 (48.5%) with
detectable HIV viral load. Because patients are included in the
cohort if they are naïve to antiretroviral therapy, the population
presents a high proportion of patients with a detectable viral load.
Prevalence and Incidence of HEV
Infection
One hundred and one patients showed positivity of IgG against
HEV (11.9%; 95% CI: 9.9–14.3%). There were no variables
associated with IgG positivity in the univariate and multivariate
analyses (Table 1). Among the previously described risk factors
for HEV in HIV-infected patients, neither men who had sex
with men (MSM) nor CD4 + cell counts were associated
with a higher rate of HEV seroprevalence. Any of the patients
included in the study were positive for IgM anti-HEV. Two
patients showed detectable HEV viral load (0.23%; 95% CI: 0.0–
0.9%). Both patients were male and were negative for both IgG
and IgM antibodies.
Of the 744 patients negative for IgG antibodies at baseline, 733
(98.5%) had available serum samples in the follow-up. Forty-two
patients showed seroconversion for IgG antibodies after 1 year
of follow-up, supposing a cumulative incidence of 5.7% (95%
CI: 4.3–7.7%). Similar to the prevalence analysis, by univariate
and multivariate analysis, all factors were not associated with
HEV seroconversion during the follow-up (Table 2). One patient
showed both positive IgG and IgM antibodies but did not have
detectable HEV RNA. HEV RNA was detected in two patients,
but they were negative for IgG and IgM antibodies.
Phylogenetic Analysis
Of the 4 patients with detectable viral load in the study, three were
successfully genotyped. In two cases, viral strains were consistent
with genotype 3f (Genbank accession numbers MN914126 and
MN914127). Interestingly, in the other patient, the isolated viral
strain was consistent with genotype 3ra (Genbank accession
number MN537838) (Table 3). Phylogenetic analysis is shown
in Figure 1. No patient had a detectable HEV viral load in the
follow-up, indicating spontaneous viral clearance.
DISCUSSION
The prevalence of HEV among PLWH strongly depends on
the country of origin and the immunoassays employed in the
study. In this sense, in high endemic areas, such Africa or Asia,
the reported seroprevalence is higher than 40%; in addition,
in other regions, such as Europe, these data vary between 29
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TABLE 1 | Univariate and multivariate analysis for IgG anti-HEV at baseline.
Variable IgG anti-HEV
positive (N = 101)
IgG anti-HEV
negative (N = 744)
Univariate p-value Adjusted OR (95% CI) Multivariate p-value
Age (year), mean (SD) 36.2 (19.8) 36.3 (14.3) 0.926 0.997 (0.98–1.01) 0.652
Gender, n (%)
Male 86 (11.5) 665 (88.5) 0.236 1
Female 15 (16) 79 (84) 0.905 (0.37–2.21) 0.828
Country of origin, n (%)
Western Europe 84 (12.3) 599 (87.7) 0.917
Eastern Europe 1 (5.6) 17 (94.4)
North-Central America 0 6 (100)
Caribbean 3 (10) 27 (90)
South America 10 (11.8) 75 (88.2)
Asia 0 4 (100)
Africa 3 (16.7) 15 (83.3)
HIV acquisition route, n (%)
Heterosexual 24 (14.6) 140 (85.4) 0.643
MSM 67 (10.9) 549 (89.1)
PWID 5 (15.2) 28 (84.8)
Other 1 (20) 4 (80)
Unknown 4 (14.8) 23 (85.2)
HIV acquisition route, n (%)a
MSM 67 (10.9) 549 (89.1) 0.134 1
No MSM 34 (14.9) 172 (85.1) 0.738 (0.38–1.42) 0.363
AIDS defining criteria, n (%)
No 88 (11.5) 677 (88.5) 0.207 1
Yes 13 (16.2) 67 (83.8) 2.02 (0.99–4.13) 0.052
Time since HIV diagnosis, mean (SD) 3.67 (4.5) 3.58 (3.8) 0.823
CD4 + cell count, mean (SD)b 586 (307) 611 (292) 0.474
CD4 + cell count, n (%)b
<200 5 (9.6) 47 (90.4) 0.622
200–349 11 (16.7) 55 (83.3)
350–500 19 (12.8) 130 (87.2)
>500 50 (11.4) 389 (88.6)
CD4 + cell count, n (%)b
<200 5 (9.6) 47 (90.4) 0.824 1
≥200 80 (12.2) 574 (87.8) 0.61 (0.22–1.67) 0.343
IgG, Immunoglobulin G; HEV, hepatitis E virus; OR, odds ratio; SD, standard deviation; n, number of patients; HIV, human immunodeficiency virus; MSM, men who have
sex with men; PWID, people who inject drugs. aTwenty-seven patients with unknown acquisition routes were excluded from the analysis. bOne-hundred and thirty nine
patients did not have CD4 + cell values.
and 10% (World Health Organization [WHO], 2014). Our study
found a Spanish seroprevalence of HEV infection of 11.9% and
a cumulative incidence of 5.9% in 1 year. These results suggest
widespread circulation of HEV among PLWH in Spain.
The main route of transmission of the HEV genotype 3 is
the consumption of raw or undercooked meat, including game
species and pork (Aspinall et al., 2017; Faber et al., 2018). In
two large case series reported in France and Switzerland, the
major subtype belonged to clade 3efg and the emerging subtype
3s, respectively (Abravanel et al., 2017; Sahli et al., 2019). In a
large temporal series in Belgium, the majority of patients were
infected by genotype 3f (Suin et al., 2019). Interestingly, these
studies found several cases of HEV infection due to the viral
genotype 3ra, whose main host are rabbits. Our study identified
one case of HEV infection by genotype 3ra, confirming the
zoonotic role of this genotype and the first description of a case
of its type in Spain. It should be highlighted that the viral strain
identified in our study shows a high similarity with two viral
strains isolated in France (MG211750 and MG211751; Figure 1),
suggesting the widespread of this strain in Europe. Remarkably,
none of the cases found in France and Switzerland documented
the consumption of rabbit meat or were in contact with them
(Abravanel et al., 2017; Sahli et al., 2019). We cannot determine
the source of infection because of the retrospective character of
the analysis of the study. Further investigations are needed to
evaluate other possible routes of infection of this genotype in
addition to consumption or contact with rabbits. Remarkably,
in these series, the rate of chronic infection among patients
infected with genotype 3ra is higher than those observed in other
subtypes. Presently, several cases of chronic HEV infection have
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TABLE 2 | Univariate and multivariate analysis for IgG anti-HEV seroconversion during follow-up.
Variable IgG anti-HEV
positive (N = 42)
IgG anti-HEV
negative (N = 691)
Univariate p-value Adjusted OR (95% CI) Multivariate p-value
Age (year), mean (SD) 36 (21) 36 (14) 0.279 0.99 (0.96–1.02) 0.735
Gender, n (%)
Male 37 (5.6) 619 (94.4) 0.794 1
Female 5 (6.5) 72 (93.5) 0.99 (0.21–4.67) 0.998
Country of origin, n (%)
Western Europe 34 (5.8) 557 (94.2) 0.463
Eastern Europe 0 17 (100)
North-Central America 0 2 (100)
Caribbean 3 (11.5) 23 (88.5)
South America 4 (5.5) 69 (94.5)
Asia 1 (25) 3 (75)
Africa 0 15 (100)
HIV acquisition route, n (%)
Heterosexual 9 (6.5) 129 (93.5) 0.518
MSM 30 (5.5) 511 (94.5)
PWID 1 (3.6) 27 (96.4)
Other 1 (25) 3 (75)
Unknown 1 (4.5) 21 (95.5)
HIV acquisition route, n (%)a
MSM 30 (5.5) 511 (94.5) 0.652 1 0.205
No MSM 11 (6.5) 159 (93.5) 0.44 (0.12–1.56)
AIDS defining criteria, n (%)
No 38 (5.7) 628 (94.3) 0.788 1
Yes 4 (6) 63 (94) 2.11 (0.56–7.92) 0.267
Time since HIV diagnosis, mean (SD) 5.4 (6.9) 3.5 (3.8) 0.081 1.05 (0.96–1.16) 0.245
CD4 + cell count, mean (SD)b 630 (238) 672 (280) 0.662
CD4 + cell count, n (%)b
<200 1 (7.1) 13 (92.9) 0.909
200–349 1 (3.4) 28 (96.6)
350–500 6 (6.5) 86 (93.5)
>500 19 (5.2) 344 (94.8)
CD4 + cell count, n (%) b
<200 1 (7.1) 13 (92.9) 0.547
≥200 26 (5.4) 458 (94.6)
IgG, Immunoglobulin G; HEV, hepatitis E virus; OR, odds ratio; SD, standard deviation; n, number of patients; HIV, human immunodeficiency virus; MSM, men who have
sex with men; PWID, people who inject drugs. aSixteen patients with unknown acquisition routes were excluded from the analysis. bTwo-hundred and fifty-one patients
did not have CD4 + cell values.
TABLE 3 | Characteristics of patients with detectable HEV RNA.
ID City Country of origin Year of sampling Gender Age HEV viral load (IU/mL) HEV genotype
545 Madrid Germany 2014 Male 43 10,376 3f
85 Tarragona Spain 2014 Male 52 217,024 3ra
420 Madrid Spain 2015 Male 43 24,387 3f
466 Murcia Nigeria 2015 Female 36 3,197 Ungenotyped
ID, identification number; HEV, hepatitis E virus; IU/mL, International Unit per milliliter.
been reported in PLWH (Rivero-Juarez et al., 2019). In our study,
none of the patients with detectable HEV viral loads developed
chronic infections, including those infected with emergence
genotype 3ra. Therefore, chronic HEV infection seems to be a
rare event in PLWH.
On the other hand, there are several variables related to
HIV infection that could be associated with a higher risk for
HEV infection in this population. In this sense, the association
between the CD4 + cell count and the seroprevalence of HEV
is controversial. There are studies that found no differences in
the rate of HEV IgG antibodies and the CD4 + cell count
(Pineda et al., 2014; Rivero-Juarez et al., 2015; Zeng et al.,
2017). Other studies found that this variable could influence a
higher or lower rate of infection (Kenfak-Foguena et al., 2011;
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FIGURE 1 | Molecular phylogenetic analysis by Maximum Likelihood method. The evolutionary history was inferred by using the Maximum likelihood method based
on the Tamura-Nei model. The bootstrap consensus tree inferred from 1000 replicates is taken to represent the evolutionary history of the taxa analyzed. Branches
corresponding to partitions reproduced in less than 50% bootstrap replicates are collapsed. Initial tree(s) for the heuristic search were obtained automatically by
applying the Neighbor-Joining and BioNJ algorithms to a matrix of pairwise distances estimated using the Maximum Composite Likelihood (MCL) approach and then
selecting the topology with superior log likelihood value. The analysis involved 120 nucleotide sequences. The codon positions included were
1st + 2nd + 3rd + Non-coding. All positions containing gaps and missing data were eliminated. Novel subtypes sequences proposed by HEVnet are referred in the
tree as p.
Zhou et al., 2018). Our study did not find any association
between the CD4 + cell count, using different cut-offs, and
the presence of IgG antibody, either in the baseline or during
the follow-up. In the same way, it is controversial whether
MSM constituted a risk population for HEV infection. Studies
conducted in Europe report a higher HEV seroprevalence in
MSM than in non-MSM populations (Payne et al., 2013; Lanini
et al., 2015). In our study, MSM showed a similar HEV
seroprevalence and seroincidence to non-MSM. This finding is
consistent with a recent study conducted in Asia, where MSM
did not show a higher risk for HEV infection in comparison
with non-MSMs (Lin et al., 2019), unlike other enteric viruses,
such as hepatitis A.
Several limitations should be noted. First, despite the high
number of hospitals involved in the present study, there is a
lack of patients from different regions. Therefore, our study
lacks the power to identify differences in prevalence between
regions. Finally, due to the anonymous character of the samples,
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additional patient data (such epidemiological variables related to
risk for HEV acquisition) cannot be evaluated.
CONCLUSION
In conclusion, our study found that HEV infection in PLWH
from Spain is frequent, showing a relatively high annual
incidence. Despite the number of acute infections identified in
our study, none of the cases involved chronic infection. We
identified one case of infection by the HEV genotype 3ra, the
main host of which is the rabbit, confirming the zoonotic role of
this emerging genotype.
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